The FDA has expanded the indication for Exelon Patch (rivastigmine transdermal system) to include the treatment of people with severe Alzheimer’s disease with Exelon Patch 13.3mg/24h.

RELATED: Neurological Resource Center

Exelon Patch is now the only transdermal therapy approved for mild, moderate, and severe Alzheimer’s disease. Rivastigmine is an acetylcholinesterase inhibitor that is thought to increase the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase, thus enhancing cholinergic function.  

The approval of Exelon Patch for severe Alzheimer’s disease was based on the randomized, double-blind ACTION (ACTivities of Daily Living and CognitION in Patients with Severe Dementia of the Alzheimer’s Type) study. Data showed that Exelon Patch 13.3mg/24h demonstrated statistically significant improvement in overall cognition and function in severe Alzheimer’s disease patients vs. the 4.6mg/24h dose at Week 24.

Exelon Patch is also approved to treat patients with mild-to-moderate dementia associated with Parkinson’s disease.

For more information call (800) 693-9993 or visit